| 1. |
- Cano, Z., et al.
(författare)
-
A trio of gamma-ray burst supernovae : GRB 120729A, GRB 130215A/SN 2013ez, and GRB 130831A/SN 2013fu
- 2014
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 568
-
Tidskriftsartikel (refereegranskat)abstract
- We present optical and near-infrared (NIR) photometry for three gamma-ray burst supernovae (GRB-SNe): GRB 120729A, GRB 130215A/SN 2013ez, and GRB 130831A/SN 2013fu. For GRB 130215A/SN 2013ez, we also present optical spectroscopy at t-t(0) = 16.1 d, which covers rest-frame 3000-6250 angstrom. Based on Fell lambda 5169 and Sill lambda 6355, our spectrum indicates an unusually low expansion velocity of similar to 4000-6350 km s(-1), the lowest ever measured for a GRB-SN. Additionally, we determined the brightness and shape of each accompanying SN relative to a template supernova (SN 1998bw), which were used to estimate the amount of nickel produced via nucleosynthesis during each explosion. We find that our derived nickel masses are typical of other GRB-SNe, and greater than those of SNe Ibc that are not associated with GRBs. For GRB 130831A/SN 2013fu, we used our well-sampled R-band light curve (LC) to estimate the amount of ejecta mass and the kinetic energy of the SN, finding that these too are similar to other GRB-SNe. For GRB 130215A, we took advantage of contemporaneous optical/NIR observations to construct an optical/NIR bolometric LC of the afterglow. We fit the bolometric LC with the millisecond magnetar model of Zhang & Meszros (2001, ApJ, 552, L35), which considers dipole radiation as a source of energy injection to the forward shock powering the optical/NIR afterglow. Using this model we derive an initial spin period of P = 12 ms and a magnetic field of B = 1.1 x 10(15) G, which are commensurate with those found for proposed magnetar central engines of other long-duration GRBs.
|
|
| 2. |
|
|
| 3. |
- Marto, João Pedro, et al.
(författare)
-
Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.
- 2023
-
Ingår i: Neurology. - 1526-632X. ; 100:7
-
Tidskriftsartikel (refereegranskat)abstract
- COVID-19-related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19.This was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT).Of a total of 15,128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19; of those, 5,848 (38.7%) patients received IVT-only and 9,280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted OR 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour mortality (OR 2.47; 95% CI 1.58-3.86), and 3-month mortality (OR 1.88; 95% CI 1.52-2.33). Patients with COVID-19 also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60).Patients with AIS and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 patients receiving treatment. Current available data do not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in patients with COVID-19 or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring, and establishing prognosis.The study was registered under ClinicalTrials.gov identifier NCT04895462.
|
|
